Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesIsland Pharmaceuticals Ltd

Island Pharmaceuticals Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.315 AUD -0.01 ( 1.56%)
Last update at 2026-11-12T04:30:00Z
VOLUME
41907
Market Cap
99.19M

Momentum Score

…

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company's lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.31
Low
0.32
High
52 Week Price Range
0.26
Low
0.63
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Island Pharmaceuticals Limited (ASX: ILA) is an Australian-listed company in the pharmaceutical sector; available public information about its pipeline, products and operations is limited. Long-term growth drivers may include successful clinical development, regulatory approvals and commercial partnerships, and investors may find the company attractive if it achieves development milestones and secures financing or licensing arrangements.
Primary risks include limited disclosed operational and financial information, dependence on successful clinical or regulatory outcomes, funding and dilution risk, and low liquidity on the ASX.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.32
Dividend Yield
-
Revenue TTM
0.28M
Revenue Per Share
0.00
Gross Profit TTM
-2.58M
Debt / Equity
0.28
ROE
-95.51%
Net Debt
-12.87M
ROCE
-78.89%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.13M -3.92M -2.86M -2.83M -2.61M
Net income -9.84M -3.92M -2.86M -2.83M -2.61M
Selling general administrative - 1.97M 1.44M 1.77M 1.60M
Selling and marketing expenses - 0.69M 0.35M - -
Gross profit -0.11M -1.29M -1.01M 0.01M -
Ebit -10.62M - -2.86M -2.90M -2.81M
Ebitda -10.51M - -2.82M -2.82M -2.81M
Depreciation and amortization 0.11M 3.96M 0.05M - -
Operating income -10.62M -5.36M -5.14M -2.90M -2.81M
Other operating expenses 10.62M 5.48M 4.13M - 2.81M
Interest expense - 0.03M 0.05M 0.01M 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.02M 0.00M 0.07M 0.20M
Net interest income - - -0.04M -0.01M -
Income tax expense -0.28M - -1.25M - -
Total revenue - 0.12M 1.25M 0.01M 0.00M
Total operating expenses 10.51M 4.07M 4.13M - 2.81M
Cost of revenue 0.11M 1.40M 2.26M - -
Total other income expense net 0.49M 1.44M 0.01M 0.08M 0.20M
Net income from continuing ops - - -2.86M -2.83M -2.61M
Net income applicable to common shares - -3.92M -2.86M -2.83M -2.61M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 14.00M 7.49M 2.56M 2.05M 4.90M
Intangible assets 0.74M - - - -
Other current assets 0.10M 0.06M 0.01M - -
Total liab 0.54M 0.34M 1.05M 0.26M 0.58M
Total stockholder equity 13.46M 7.16M 1.52M 1.79M 4.32M
Other current liab 0.38M 0.19M 0.31M 0.00M 0.34M
Common stock 42.91M 31.63M 22.39M 19.90M 19.90M
Capital stock - - - 19.90M 19.90M
Retained earnings -34.90M -25.08M -21.20M -19.76M -4.73M
Cash 12.87M 7.25M 1.66M 2.00M 4.79M
Total current liabilities 0.54M 0.34M 1.05M 0.26M 0.58M
Net debt -12.87M -7.25M -1.24M - -4.79M
Short term debt - - 0.42M 0.00M 0.00M
Short long term debt total - - 0.42M - -
Other stockholder equity - - - 1.65M -10.85M
Total current assets 13.26M 7.49M 2.56M 2.05M 4.90M
Net tangible assets - - - 1.79M 4.32M
Net receivables 0.29M 0.18M 0.89M 0.02M 0.02M
Accounts payable 0.16M 0.15M 0.31M 0.11M 0.24M
Accumulated other comprehensive income 5.44M 0.61M 0.33M - -10.85M
Non current assets total 0.74M - - 0.00M 0.00M
Long term debt total - - - 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Change to liabilities - - - -0.33M 0.31M
Total cashflows from investing activities -0.84M 0.00M 0.00M 0.00M 0.00M
Net borrowings - - 0.20M - -
Total cash from financing activities 11.11M 8.36M 2.79M -0.18M -0.18M
Change to operating activities - - - 0.07M 0.06M
Net income -9.84M -3.92M -2.86M -2.83M -2.61M
Change in cash 5.62M 5.59M -0.34M -2.79M -1.67M
Begin period cash flow 7.25M 1.66M 2.00M 4.79M 6.46M
End period cash flow 12.87M 7.25M 1.66M 2.00M 4.79M
Total cash from operating activities -4.83M -2.77M -3.16M -2.70M -1.88M
Issuance of capital stock - - 2.73M - -
Depreciation 0.11M - - - -
Other cashflows from investing activities - 0.00M 0.00M 0.00M 0.00M
Change to account receivables -0.11M 0.71M -0.87M 0.00M 0.04M
Sale purchase of stock - 9.05M -0.13M - 0.00M
Other cashflows from financing activities 0.00M 0.01M -0.01M -0.18M -0.18M
Change to netincome - - - 0.39M 0.32M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.04M 0.64M -0.85M -2.70M -1.88M
Stock based compensation - 0.34M - - -
Other non cash items 4.86M 0.18M 0.55M - -
Free cash flow -4.83M -2.77M -3.16M -2.70M -1.88M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ILA
Island Pharmaceuticals Ltd		 -0.01
1.56%		 0.32 - - 350.93 6.38 258.25 -0.68
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Island Pharmaceuticals Ltd

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company's lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.

117 Camberwell Road, Hawthorn East, VIC, Australia, 3123

61 3 7036 7675

https://www.islandpharmaceuticals.com

Name Title Year Born
Dr. Paul Donald Richard MacLeman M.B.A., MBA, BVSc, Grad Dip Tech, Grad Cert Eng, G Exec. Chairman 1966
Dr. David Charles Foster MD, CEO, Pres & Exec. Director NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963
Dr. Paul Donald Richard MacLeman BVSc, D.V.M., F.A.C.I.D., GAICD, Grad Cert Eng, Gr Executive Chairman 1966
Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D. MD, CEO, President & Executive Director NA
Mr. Cameron Jones C.A. Joint Company Secretary NA
Stephanie Vipond Joint Company Secretary NA
Dr. Paul Donald Richard MacLeman BVSc, D.V.M., F.A.C.I.D., GAICD, Grad Cert Eng, Gr Executive Chairman 1966
Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D. MD, CEO, President & Executive Director NA
Mr. Cameron Jones C.A. Joint Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…